for people ages 18 years and up (full criteria)
at UC Davis
study started
estimated completion
Principal Investigator
by Hui Amy Chen, MD (ucdavis)



IMC-C103C is an immune mobilizing T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen MAGE-A4. This is a first-in-human trial designed to evaluate the safety and efficacy of IMC-C103C in adult patients who have the appropriate HLA-A2 tissue marker and whose cancer is positive for MAGE-A4.

Official Title

A Phase 1/2 First-in-human Study of the Safety and Efficacy of IMC-C103C as Single Agent and in Combination With Atezolizumab in HLA-A*0201-positive Patients With Advanced MAGE-A4-positive Cancer


The IMC-C103C-101 Phase 1/2 study will be evaluated in patients with metastatic/unresectable tumors which include select Advanced Solid Tumors and will be conducted in two phases. 1. To identify the MTD and/or RP2D of IMC-C103C as a single agent administered Q1W (Arm A1) and administered Q1W in combination with Q3W atezolizumab (Arm A2). 2. To assess the preliminary anti-tumor activity of IMC C103C in one or more selected indications, as a single agent administered Q1W (Arm B1) and administered Q1W in combination with Q3W atezolizumab (Arm B2).


Select Advanced Solid Tumors ImmTAC, IMC-C103C, MAGE-A4, immunotherapy Atezolizumab IMC-C103C


You can join if…

Open to people ages 18 years and up

  1. HLA-A*02:01 positive
  2. MAGE-A4 positive tumor
  3. ECOG PS 0 or 1
  4. Selected advanced solid tumors
  5. Relapsed from, refractory to, or intolerant of standard therapy
  6. Measurable disease per RECIST v1.1
  7. If applicable, must agree to use highly effective contraception

You CAN'T join if...

  1. Symptomatic or untreated central nervous system metastasis
  2. Inadequate washout from prior anticancer therapy
  3. Significant ongoing toxicity from prior anticancer treatment
  4. Impaired baseline organ function as evaluated by out-of-range laboratory values
  5. Clinically significant cardiac disease
  6. Active infection requiring systemic antibiotic therapy
  7. Known history of human immunodeficiency virus (HIV)
  8. Active hepatitis B virus (HBV) or hepatitis C virus (HCV)
  9. Ongoing treatment with systemic steroids or other immunosuppressive therapies
  10. . Significant secondary malignancy
  11. . Pregnancy or lactation


  • University of California Davis Comprehenvise Cancer Center accepting new patients
    Sacramento California 95817 United States
  • The Angeles Clinic and Research Institute accepting new patients
    Los Angeles California 90025 United States

Lead Scientist at University of California Health


accepting new patients
Start Date
Completion Date
Immunocore Ltd
Phase 1/2
Study Type
Last Updated